DexCom Inc.
Organization details
- Legal name
- DexCom Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 3841 — Surgical & Medical Instruments & Apparatus
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- DXCM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001093557
- EIN
- 33-0857544
- Wikidata ID
- Q15109865
Board of directors
-
Albert Frederick Osterloh IV · DirectorSince 2026
-
Barbara Kahn · DirectorSince 2023
-
Bridgette P. Heller · DirectorSince 2023
-
Eric Topol · DirectorSince 2023
-
Euan A. Ashley · DirectorSince 2025
-
Glenn S. Boehnlein · DirectorSince 2026
-
Jacob Steven Leach · Director · President, CEO, and DirectorSince 2026
-
Jay S. Skyler · DirectorSince 2023
-
Karen M. Dahut · DirectorSince 2023
-
Kevin R. Sayer · Director · Executive ChairSince 2023
-
Kyle Malady · DirectorSince 2023
-
Mark G. Foletta · DirectorSince 2023
-
Nicholas Augustinos · DirectorSince 2023
-
Renee D. Gala · DirectorSince 2025
-
Richard Alexander Collins · DirectorSince 2023
-
Rimma Driscoll · DirectorSince 2023
-
Steven R. Altman · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 27, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.7%
-
94.5%
-
95.1%
-
96.0%
-
97.8%
-
98.2%
-
98.5%
-
99.3%
-
99.7%
-
99.7%
-
99.8%
Board connections
6 of this board's directors also sit on 9 other boards. 5 are in the same sector.
- via Mark G. Foletta
- via Glenn S. Boehnlein
- via Bridgette P. Heller
-
Enanta Pharmaceuticals Inc. Same sectorvia Mark G. Foletta
-
Gossamer Bio Inc. Same sectorvia Renee D. Gala
-
Inogen Inc Same sectorvia Glenn S. Boehnlein
-
Jazz Pharmaceuticals plc Same sectorvia Renee D. Gala
-
SAB Biotherapeutics Inc. Same sectorvia Jay S. Skyler
- via Jacob Steven Leach
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $12,753,176
- 31 sales by 9 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 8, 2026 | Brown Michael Jon Officer (EVP Chief Legal Compliance Off) | Shares withheld for tax | −1,451 | $79.41 | $115,224 |
| Nov 8, 2026 | Sylvain Jereme M Officer (EVP, COO & CFO) | Shares withheld for tax | −1,451 | $79.41 | $115,224 |
| Nov 8, 2026 | Stern Sadie Officer (EVP Chief People & Culture Off) | Shares withheld for tax | −1,451 | $79.41 | $115,224 |
| Nov 8, 2026 | Jacob Steven Leach Director, Officer (President, CEO, and Director) | Shares withheld for tax | −1,451 | $79.41 | $115,224 |
| Oct 30, 2026 | Euan A. Ashley Director | Gift | −2,389 | — | — |
| Oct 27, 2026 | Stern Sadie Officer (EVP Chief People & Culture Off) | Open-market sale | −2,565 | $78.62 | $201,660 |
| Oct 15, 2026 | Brown Michael Jon Officer (EVP Chief Legal Compliance Off) | Open-market sale | −1,700 | $85.48 | $145,316 |
| Sep 28, 2026 | Stern Sadie Officer (EVP Chief People & Culture Off) | Open-market sale | −2,565 | $86.15 | $220,975 |
| Sep 15, 2026 | Brown Michael Jon Officer (EVP Chief Legal Compliance Off) | Open-market sale | −1,700 | $84.04 | $142,868 |
| Sep 15, 2026 | Nicholas Augustinos Director | Open-market sale | −6,539 | $84.04 | $549,538 |
| Sep 14, 2026 | Nicholas Augustinos Director | Open-market sale | −1,550 | $84.02 | $130,231 |
| Sep 10, 2026 | Glenn S. Boehnlein Director | Grant or award | +5,841 | — | — |
| Sep 10, 2026 | Sylvain Jereme M Officer (EVP, Chief Financal Officer) | Open-market sale | −3,638 | $83.27 | $302,936 |
| Aug 27, 2026 | Stern Sadie Officer (EVP Chief People & Culture Off) | Open-market sale | −2,565 | $88.37 | $226,669 |
| Aug 22, 2026 | Brown Michael Jon Officer (EVP Chief Legal Compliance Off) | Shares withheld for tax | −1,451 | $92.34 | $133,985 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about DexCom Inc.
Who is the CEO of DexCom Inc.?
Kevin R. Sayer is DexCom Inc.'s President CEO and Chairman of.
How many directors are on DexCom Inc.'s board?
DexCom Inc.'s board has 17 directors: Albert Frederick Osterloh IV, Barbara Kahn, Bridgette P. Heller, Eric Topol, Euan A. Ashley, Glenn S. Boehnlein, Jacob Steven Leach, Jay S. Skyler, Karen M. Dahut, Kevin R. Sayer and 7 others.
Are DexCom Inc. insiders buying or selling shares?
Over the last 12 months, DexCom Inc. insiders made no open-market purchases and sold $12.8 million of shares in 31 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="dexcom-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.